Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up

Creative Commons License

Yetgin S., Tuncer M., Cetin M., Gumruk F., Yenicesu I., Tunc B., ...Daha Fazla

LEUKEMIA, cilt.17, sa.2, ss.328-333, 2003 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 2
  • Basım Tarihi: 2003
  • Doi Numarası: 10.1038/sj.leu.2402673
  • Dergi Adı: LEUKEMIA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.328-333
  • Anahtar Kelimeler: high-dose methylprednisolone (HDMP), children, ACUTE LYMPHOCYTIC-LEUKEMIA, GLUCOCORTICOID RECEPTORS, STEROID-HORMONES, PERIPHERAL-BLOOD, POOR PROGNOSIS, L-ASPARAGINASE, CHILDREN, CHEMOTHERAPY, CELLS, BIOLOGY
  • Marmara Üniversitesi Adresli: Hayır

Özet

Eight-year event-free survival (EFS) was evaluated in 205 patients with acute lymphoblastic leukemia (ALL), to consider the efficacy of high-dose methylprednisolone (HDMP) given during remission induction chemotherapy between 1 and 29 days. The St Jude Total XI Study protocol was used after some minor modifications in this trial. Patients were randomized into two groups. Group A (n = 108) received conventional dose (60 mg/m(2)/day orally) prednisolone and group B (n = 97) received HDMP (Prednol-L, 900-600 mg/m(2) orally) during remission induction chemotherapy. Complete remission was obtained in 95% of the 205 patients who were followed-up for 11 years; median follow-up was 72 months (range 60-129) and 8-year EFS rate was 60% overall (53% in group A, 66% in group 13). The EFS rate of group B was significantly higher than of group A (P = 0.05). The 8-year EFS rate of groups A and B in the high-risk groups was 39% vs 63% (P = 0.002). When we compared 8-year EFS rate in groups A and B in the high-risk subgroup for both ages together less than or equal to2 or greater than or equal to10 years, it was 44% vs 74%, respectively. Among patients in the high-risk subgroup with a WBC count greater than or equal to50 x 10(9)/l, the 8-year EFS was 38% in group A vs 58% in group B. During the 11-year follow-up period, a total of 64 relapses occurred in 205 patients. In group A relapses were higher (39%) than in group B (23%) (P = 0.05). These results suggest that HDMP during remission-induction chemotherapy improves the EFS rate significantly for high-risk patients in terms of the chances of cure.